SCHEMBL9978657

SCHEMBL9978657

FC[CH]c1ccccn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL270008 0.79
SCHEMBL947177 0.77
SCHEMBL4967243 0.77
SCHEMBL28804397 0.77 MEN1 (0.52)
SCHEMBL4651571 0.76 MEN1 (0.56)
SCHEMBL229328 0.75 NPC1 (1.00)
SCHEMBL31560044 0.75 NPC1 (1.00)
SCHEMBL9394256 0.75 NPC1 (1.00)
SCHEMBL229329 0.75 NPC1 (1.00)
SCHEMBL8670245 0.74 MEN1 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102803204-A Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds GILEAD COLORADO INC 2012-11-28 CN claimed
EP-2576576-A1 HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF The Royal Institution for the Advancement of Learning/McGill University (CA) 2013-04-10 EP disclosed
CN-102803204-A Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds GILEAD COLORADO INC 2012-11-28 CN disclosed
WO-2011147038-A1 HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2011-12-01 WO disclosed